Trials / Unknown
UnknownNCT03196830
CAR-T for R/R B-NHL
Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 6 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T | For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2021-05-31
- Completion
- 2021-05-31
- First posted
- 2017-06-23
- Last updated
- 2019-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03196830. Inclusion in this directory is not an endorsement.